We examined the potential of interferon gamma (IFN-gamma) to ameliorate the physiologic defect of chronic granulomatous disease (CGD) by studying its effects on CGD phagocyte superoxide generation, NADPH oxidase kinetics, cytochrome b559 content, and expression of X-CGD (the gene for the Xlinked disease). Granulocytes and macrophages from three patients in two kindreds with "variant" X-linked CGD (i.e., with very low, but detectable, baseline superoxide-generating activity) responded to IFN-gamma with enhanced nitroblue tetrazolium reduction and two-to eightfold increases in superoxide generation. IFN-gamma did not augment the respiratory burst activity of phagocytes from patients with "classic" CGD (i.e., no detectable baseline superoxide generation) or autosomal variant CGD. Incubation of a responding patient's granulocytes with IFN-gamma nearly doubled the maximal velocity for the NADPH oxidase, but did not change its abnormal Michaelis constant. Although the interferon-treated CGD granulocytes produced superoxide at a rate 40% of normal, the cytochrome b spectrum remained undetectable. IFN-gamma treatment of cultured monocytes from an IFN-gamma-responsive CGD patient increased the steady state level of RNA transcripts from the X-CGD gene from barely detectable up to -5% of normal.
Introduction
Phagocytic cells, such as macrophages and polymorphonuclear leukocytes (PMN), produce reactive oxygen intermediates with microbicidal, tumoricidal and inflammatory effects (1, 2) . The initial step in their formation is the one-electron reduction of oxygen to superoxide, catalyzed by a membrane-associated NADPH oxidase. The enzyme system is inactive in resting cells, but is rapidly activated upon exposure to a variety of particulate and soluble stimuli that act though several alternative pathways of transmembrane signal trans-duction (3) (4) (5) . Regulation of NADPH oxidase activity includes not only activation, but also processes of priming (6) and deactivation (7) .
In chronic granulomatous disease (CGD),' phagocytes fail to produce superoxide and its oxygen metabolites (8, 9) . Thus, PMN and macrophages from these patients ingest particles and degranulate normally, but fail to kill microorganisms (10) . This defect in host defense results in recurrent, and sometimes fatal, purulent infections beginning early in childhood (11) . The disease exhibits heterogeneity ofinheritance, with the majority of cases being X-linked and a minority, autosomal recessive (12) . In most (13) , but not all (14) , X-linked kindreds, patients' phagocytes lack spectrally detectable cytochrome b559, a heme-containing protein that has been proposed as a critical terminal component of the oxidase system (15, 16) . Recently, molecular cloning of the X-CGD gene (the gene for the X-linked disease) and its cDNA has been accomplished (17) . The protein product of the X-CGD gene is predicted to be a 58-kd basic polypeptide that contains several potential glycosylation sites and bears no homology to known proteins, including cytochromes. Antibodies raised to a synthetic peptide derived from the predicted sequence assign the in vivo gene product as a glycosylated 90-kd membrane protein (18) . This species forms part of the neutrophil cytochrome b559 heterodimer, which consists of the 90-kd glycoprotein and a 22-kd nonglycolsylated polypeptide (19) . Both components are absent from PMN of patients with X-linked CGD (20) . In contrast, PMN from most patients with the autosomal recessive disease contain normal cytochrome b559, but lack a soluble activation factor (21) and fail to phosphorylate a protein with an apparent molecular weight of 44,000 (22) . The molecular basis for this form of the disease remains unknown.
In addition to these "classic" forms of CGD, several "variants" have been reported, all with decreased but detectable neutrophil O2 production (23) (24) (25) (26) (27) (28) . Most of these patients presented later in life, with milder clinical disease, than classic CGD patients. Their neutrophils showed altered NADPH oxidase kinetics, which consists of an elevated Michaelis constant (KmaPP, reflecting decreased affinity for NADPH) with (24) or without (23, 25, 26) a decreased maximum velocity (Vma,). In most of the X-linked cases (23, 24, 28) cytochrome b559 was undetectable, but in one of the X-linked (27) and the autosomal recessive cases (25) the cytochrome content was normal.
Most likely, these variants represent the currently detectable end ofa spectrum ofX-CGD gene expression, analogous to the range of beta thalassemia or hemophilia A.
Previous work in our laboratory (Newburger, P. E., S. H. Orkin, and R. A. B. Ezekowitz. Unpublished data) has shown an increase in steady state levels of RNA derived from the X-CGD gene in normal cultured monocyte-derived macrophages incubated with interferon gamma (IFN-gamma). Also, the difference in superoxide production and substrate affinity between the NADPH oxidases of CGD variant and normal neutrophils is similar to that between the NADPH oxidases of resting and IFN-gamma-activated cultured macrophages (29, 30) . Further, Berton et al. have recently demonstrated the ability of IFN-gamma to enhance respiratory burst activity in neutrophils as well (31) . We therefore explored the potential of IFN-gamma to ameliorate the physiologic defect of CGD by studying its effects on CGD phagocyte superoxide generation, NADPH oxidase kinetics, cytochrome b559 content, and X-CGD gene expression.
Methods
Media and reagents. RPMI 1640 was obtained from Grand Island Biological Co., Grand Island, NY; cytochrome c, phorbol myristate acetate (PMA), nitroblue tetrazolium (NBT), superoxide dismutase, Triton X-100, Triton X-l 14, and zymosan, from Sigma Chemical Co., St. Louis, MO; ficoll 400 and dextran 500 from Pharmacia Fine Chemicals, Piscataway, NJ; and sodium hypaque, 50%, from Winthrop Laboratories, New York, NY.
Recombinant human INF-alpha, -beta, and -gamma were obtained from Genentech, Inc., San Francisco, CA, and from Dr. P. Trown, Hoffmann-La Roche, Inc., Nutley, NJ; all contained < 2 EU endotoxin/mg interferon (< 1 EU/107 U interferon) as determined by limulus amoebocyte lysate assay. Interferon stock solutions of 106 and 102 U/,ul in RPMI 1640 were stored at -80°C and 4°C, respectively, and the latter diluted to final concentrations immediately before use.
Cells. Peripheral venous blood in acid-citrate-dextrose anticoagulant was obtained from CGD patients, normal volunteer donors, and the granulocyte and mononuclear cell fractions isolated by dextran sedimentation and Ficoll-Hypaque centrifugation (32 Assays. For NBT-reduction assays, granulocytes or macrophages were cultured as above, but on sterile glass coverslips, then incubated for 15 min at 370C in Krebs-Ringer phosphate buffer with 5 mM glucose containing NBT and either PMA (100 ng/ml) or opsonized zymosan (10 ,g/ml) as previously described (33) . Two investigators examined the coverslips by phase microscopy, and scored NBT reduction in each experimental group on a semiquantitative five-point scale (0 to ++++). Scoring was confirmed by a third independent observer, familiar with the NBT method and blinded to the experimental design.
Superoxide generation was measured by a discontinuous assay of superoxide dismutase-inhibitable ferricytochrome c reduction, as previously described (33) except for the use of PMA (100 ng/ml) or serum-opsonized zymosan (I mg/ml) as stimulants.
Granulocyte NADPH oxidase activity and kinetics were measured as NADPH-dependent superoxide dismutase-inhibitable cytochrome c reduction at 28°C in particulate fractions from PMA-stimulated neutrophils (34) (35) (36) . The NADPH concentration was varied from 0.1 to 5 mM and the data analyzed by the method ofLineweaver and Burk (37) . Before PMA stimulation, the PMN were incubated (as above) for 3 h at 37°C with or without IFN-gamma 500 U/ml.
Cytochrome b559 content was measured in whole granulocytes by anaerobic-aerobic and dithionite-aerobic difference spectroscopy of cell suspensions in phosphate-buffered saline with and without 0.2% (vol/vol) Triton X-100, as previously described (35) . Cytochrome b559 was also extracted and concentrated from cell sonicates with Triton X-l 14 (38) and then spectrophotometrically assayed as above.
Monocyte-derived macrophages for messenger RNA (mRNA) analysis were cultured in plastic tissue culture wells, as previously described (33) , with or without IFN-gamma 100 U/ml. At day 8 of culture, cells were scraped directly into 6 M guanidine HCI, and RNA was extracted by ethanol precipitation from guanidine HO as described by Ginsburg et al. (39) . Parallel wells were assayed for NBT reduction to confirm the interferon effect for each experiment. Total cellular RNA was examined by Northern blot analysis (40), using randomly primed (36, 41) complementary DNA probes for sequences from X-CGD (17) and constitutively expressed genes for phosphoglycerate kinase (42) .
Results
NBT reduction. The histochemical NBT test semiquantitatively measures respiratory burst activity in individual cells (33, 35) . As shown in Table I Incubation of PMN and macrophages with IFN-alpha and -beta produced no augmentation of NBT reduction (data not shown).
Superoxide production. We next quantitatively examined superoxide generation by a spectrophotometric assay of superoxide dismutase-inhibitable cytochrome c reduction. Table II shows that superoxide production followed the same pattern as NBT reduction: IFN-gamma augmented the responses in Xlinked variant, but not classic, CGD phagocytes, and similarly affected normal macrophages. The proportional increases in superoxide generation were at least two-to threefold for PMN and two-to eightfold for macrophages; the exact relative change could not be determined because baseline responses were undetectable for most of the CGD cells. Similar results were obtained with opsonized zymosan as the stimulus (data not shown).
Normal PMN did not show enhanced superoxide generation in response to IFN-gamma, again probably due to the maximum stimulation provided by PMA and opsonized zymosan. Berton et al. detected such augmentation only with suboptimal stimuli such as chemotactic peptide or very low dose PMA (31). They, too, noted a loss of the IFN-gamma effect with higher doses of PMA.
In the absence of a respiratory burst stimulus, there was no detectable superoxide production by PMN or macrophages, whether incubated with or without IFN-gamma. That is, as previously observed (43) , IFN-gamma does not by itself activate the superoxide-generating system. IFN-alpha and -beta did not augment superoxide responses in any of the cells tested (data not shown).
NADPH oxidase kinetics. To elucidate the mechanism for the increase in superoxide production induced by IFNgamma, we examined its effect on the kinetics of granulocyte NADPH oxidase. Only patients RaJ and ReJ could donate enough blood and had shown sufficient baseline granulocyte superoxide-generating activity to provide the cell numbers and unenhanced enzyme activity necessary for kinetic studies. As shown in Fig. 2 (28) , the Vm. for NADPH oxidase from the variant CGD granulocytes was < 10% that from normal cells. Incubation for 4 h in IFN-gamma nearly doubled the maximal velocity for the CGD oxidase, but did not affect the already high velocity ofthe normal enzyme (a response pattern parallel to that described above for intact cells). IFN-gamma only slightly lowered the abnormal Km5PP of the CGD enzyme.
Although the interferon-treated CGD granulocytes produced superoxide at a rate 40% of normal, cytochrome b559 remained spectrophotometrically undetectable. As illustrated in Fig. 3 , the characteristic cytochrome b difference spectrum of intact granulocytes was not observed either with or without IFN-gamma, in an assay capable of detecting the spectrum at an intensity 5% that of normal cells. Addition of Triton X-100 (0.02% final concentration) enhanced the 474 nm (myeloperoxidase) peak, but did not reveal any cytochrome b, nor did extraction with Triton X-114 (data not shown). Anaerobicaerobic difference spectra showed similar baseline drift but no absorption peaks (data not shown). Quantitive measurement of cytochrome b from the absorption spectra revealed no detectable content (i.e., < with the X-CGD probe and may represent mRNAs with alternative patterns of splicing.
Discussion
The respiratory burst plays a major role in the antitumor and microbicidal activity ofphagocytes (1, 2). IFN-gamma, a product of T cells and natural killer cells, enhances the respiratory burst capacity in both human and murine macrophages (44); nonimmune interferons and some products of tumor cells have the opposite effect (45, 46) . In this study we show that the respiratory burst in phagocytes from three patients with Xlinked CGD is enhanced by the addition of IFN-gamma. The low, but detectable, level of phagocyte superoxide-generating activity in these patients, thus classified as CGD variants, probably represents the upper end of a spectrum of oxidase activity in the disease. Single cell analysis of PMN revealed a homogeneous increase in NBT reduction rather than a responding subpopulation. No response to IFN-gamma was observed in phagocytes from patients with no detectable baseline respiratory burst activity (so-called classic X-linked CGD) or from patients with autosomal recessive CGD, with or without baseline respiratory burst activity. The effect of IFN-gamma required at least 40-60 min incubation for PMN and 36 h for macrophages. Quantitative measurement of superoxide generation confirmed the findings of the NBT reduction assay, and indicated the IFN-gamma-induced augmentation to be two-to threefold in PMN and two-to eightfold in macrophages.
The mechanism by which IFN-gamma augments superoxide generation by normal and X-CGD phagocytes is not known. Analysis of the kinetics of superoxide generation by NADPH oxidase showed that interferon treatment increases the Vml of the enzyme, but has little effect on the abnormally low substrate affinity (high KmaPP). The initial kinetic abnormality of these cells is characteristic of phagocytes that produce only low levels of reactive oxygen intermediates, such as normal resident macrophages and PMN from patients with so-called variant CGD (23-25, 27, 28) . Treatment of macrophages with IFN-gamma produces an increase in superoxide production, accompanied by a decrease in the Kma without much change in the V.,, of the oxidase (30) . The different pattern of kinetic response to IFN-gamma observed in the present study suggests that in X-CGD granulocytes it increases the number of active enzyme molecules per cell, but does not render them functionally normal. This discrepancy may arise from the residual CGD defect or from the difference in cell types examined. The polypeptide encoded by the X-CGD gene (for which the transcript is induced) is the larger (90 kd) oftwo proteins in the cytochrome b559 heterodimer (18) or for which small, undetectable amounts of heme are sufficient.
IFN-gamma treatment increased the very low steady state level of RNA transcripts from the X chromosome CGD gene (17) up to one that was 5% that in normal macrophages. X-CGD gene expression also increases two-to fivefold in normal monocyte-derived macrophages incubated with IFNgamma (Newburger, P. E., S. H. Orkin, and R. A. B. Ezekowitz. Unpublished data). This cytokine therefore appears to up-regulate expression ofthe X-CGD gene in both normal and CGD macrophages, either by increasing gene transcription or through posttranslational stabilization of mRNA.
However, the proportional rates of superoxide production in treated CGD cells compared with normal cells still appear to be greater than the proportional steady state levels of X-CGD transcripts. This discrepancy suggests that NADPH oxidase enzyme activity is a non-linear function ofthe level ofX-CGD RNA and its protein product, so that small increases in functional RNA transcripts produce major changes in cell function. Alternatively (or additionally), IFN-gamma may increase NADPH oxidase activity by posttranslational mechanisms (e.g., cell priming [6, 47] ) that could increase the apparent efficacy of a partially disabled oxidase. Definition of the precise mutations in the X-CGD gene from IFN-gamma-responsive and -unresponsive patients should provide insight into the molecular basis of the cellular and clinical defects in the disorder. The range of residual phagocyte oxidase activity observed in the variant CGD patients suggests that they do not represent a homogeneous subclassification of the disease, but rather a spectrum akin to the ,8 thalassemias.
Systemic IFN-gamma therapy has been used to augment hydrogen peroxide secretion by monocytes in patients with malignancy (48) . Further, local subcutaneous IFN-gamma therapy can partially correct the systemic defect in monocyte peroxide production in lepromatous leprosy (49) . These studies provide a precedent for systemic use of IFN-gamma that may eventually be applicable to the subset of X-linked CGD patients whose cells respond in vitro. This approach would represent a unique opportunity to apply in vitro molecular findings to the pharmacologic modulation of gene expression in human disease.
